



CODEN [USA]: IAJPBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

<http://doi.org/10.5281/zenodo.3819143>

Available online at: <http://www.iajps.com>

Research Article

RAISED LEVELS OF HS-CRP AND FERRITIN IN PATIENTS WITH TYPE II DIABETES MELLITUS

Dr. Anjum Zahra¹, Dr. Saad Muhammad², Dr. Muhammad Yaseen³

¹ Ghazi Medical Collage DG Khan

² King Edward Medical University, Lahore

³ Wah Medical College Wah Cantt

Article Received: March 2020

Accepted: April 2020

Published: May 2020

Abstract:

Aim: To measure very sensitive blood levels of C-reactive protein and ferritin in the blood, and to assess its association with inflammation in people with type 2 diabetes.

Method: Case control study was conducted at the Medicine Unit II of Nishtar Hospital Multan for one year duration from February 2019 to February 2020, and included randomly selected patients and healthy controls. Fasting blood samples were analyzed to determine blood sugar, insulin, very sensitive C-reactive protein and iron status. SPSS 19 was used for statistical analysis.

Results: Out of 210 originally selected patients, 99 (47%) were excluded from the study due to anemia. The study population is 111 (53%) with a total average age of 38.6 ± 1.56 years, and fasting blood sugar is 110.78 ± 3.795 mg / dl. In group 1, there were 44 (39.6%) healthy people and 67 (60.3%) diabetic patients in group 2. High serum ferritin (233.11 ± 43.84 ng / ml), insulin ($29, 94 \pm 2.19$), insulin homeostasis pattern, resistance (10.23 ± 0.89) and very sensitive C-reactive protein (5.29 ± 0.80 mg / L) low serum iron levels ($5.29 \pm 0, 80$ mg / L) 1.07 ± 0.115 µg / dl) in group 2. The insulin resistance homeostasis model showed a positive correlation with fasting blood sugar ($r = 0.596$; $p < 0.009$). There was a negative correlation with iron serum ($r = -0.280$; $p < 0.016$) and transferrin saturation ($r = -0.316$; $p < 0.006$).

Conclusion: Increased ferritin levels without visible iron overload can affect glucose homeostasis and lead to insulin resistance with inflammatory changes, as seen at high levels of C-reactive protein.

Key words: ferritin, hs-CRP, T2DM, insulin resistance.

Corresponding author:

Dr. Anjum Zahra,

Ghazi Medical Collage DG Khan

QR code



Please cite this article in press Anjum Zahra et al, **Raised Levels Of HS-CRP And Ferritin In Patients With Type II Diabetes Mellitus.**, Indo Am. J. P. Sci, 2020; 07(05).

INTRODUCTION:

Type 2 diabetes (DM2) is an important global lifestyle disorder. Asian countries make up over 60% of the world's diabetes population¹⁻³. T2DM is a complex disease that requires the interaction of genetic and environmental factors. Patients with DM2 show defects in insulin resistance (IR) and defects in beta cells. Insulin defects after cooking are usually responsible for IR in DM2⁴⁻⁶. The relationship between DM2 and iron metabolism applies to both research and clinical practice. Scientific evidence has estimated the effect of high serum ferritin levels on IR and T2DM due to increased iron stores in the body or the effect of various inflammatory diseases⁷⁻⁹. Therefore, it is assumed that circulating ferritin levels, which are also an acute phase reagent, do not reflect iron stores in the body, but may cause other processes such as systemic inflammation.

The inflammatory process induces hepatic synthesis of various acute phase proteins, such as highly sensitive creative protein (hs-CRP) and serum ferritin, which are thought to play a role in cell-level IR. Given this model, the current study aimed to associate elevated iron levels and hs-CRP levels with diabetes, and assess ferritin-IR association.

PATIENTS AND METHODS:

The case-control study was conducted at the Medicine Unit II of Nishtar Hospital Multan for one year duration from February 2019 to February 2020, it included randomly selected patients and healthy controls. In order to achieve minimum 80% power with a 13.14% estimated prevalence of disease in project area and a two-sided 5% level of significance, the minimum sample size required, according to Power and Sample Size (PASS) version 11, was 42 for each group. After randomized individuals were excluded from the general population based on total blood count (CBC) indicating iron deficiency anemia. Other people were divided into two groups. They were healthy controls in group I and DM2 in group 2.

Clinically important concomitant diseases (iron deficiency anemia, cardiovascular disease, acute infectious disease or chronic inflammatory or debilitating disease), smoking and alcoholism, and drug use (multivitamins and iron supplements). The study protocol was approved by the corporate ethics committee. After obtaining written consent of all participants, 10 ml of blood was collected from each participant. Biomarkers were analyzed in serum samples. In addition, fasting blood sugar (FBS) levels for all subjects were estimated using the glucose-oxidase-phenol-aminophenone (GOD-PAP) method (Merck, France). The IR level was calculated by assessing the insulin resistance model (HOMA-IR) [fasting insulin (units per milliliter) x milligrams / fasting glucose decision inflammation / 405] homeostasis model. Serum iron and total iron binding capacity (TIBC) was determined by the Bio Merieux method (S.A. France) by an enzymatic colorimetric method. % Transferrin saturation was calculated at 100x serum iron / TIBC.

Data were analyzed using SPSS 19. Mann Whitney U test was used for comparison between groups. The mean \pm standard deviation (SD) was calculated for quantitative variables. Spearman's correlation was applied to correlation variables, and $p < 0.05$ was considered significant.

RESULTS:

99 (47%) of the 210 initially selected patients were excluded from the study due to anemia. The study population was 111 (53%) and the overall average age was 38.6 ± 1.56 years (range: 15-65 years), and fasting blood sugar was 110.78 ± 3.795 mg / dl. Group 1 had 44 (39.6%) healthy controls, and group 2 had 67 (60.3%) diabetic patients.

Mean blood glucose levels ($p < 0.001$), insulin ($p = 0.037$), IR ($p < 0.001$), ferritin ($p < 0.001$) and hs-CRP ($p < 0.05$) were significantly higher in DM2 as compared to Control. Together with this, serum iron was significantly lower in group 2 than in group 1 ($p < 0.001$) (Table 1).

Table-1: Serum iron parameters, serum glycaemic, Anthropometric.

Parameters	Controls n= 44	Diabetics n= 67	P value
Age	29.93 \pm 1.81	47.27 \pm 1.322**	< 0.001
Weight	62.52 \pm 1.87	76.30 \pm 2.74	<0.001
Fasting blood sugar (mg/dl)	84.54 \pm 2.96	137.02 \pm 4.63**	< 0.001
Serum Insulin (IU/ml)	22.59 \pm 1.68	29.94 \pm 2.19*	0.037
Insulin resistance (HOMA-IR)	4.61 \pm 0.46	10.23 \pm 0.89**	<0.001
Serum iron (?g/dl)	2.44 \pm 0.26	1.07 \pm 0.155**	<0.001
Serum TIBC (?g/dl)	1.91 \pm 0.21	2.98 \pm 0.14**	<0.001
Serum transferrin saturation (%)	306.63 \pm 142.57	65.51 \pm 18.14**	<0.001
Serum ferritin (ng/ml)	132.45 \pm 38.08	233.11 \pm 43.84**	<0.001
hs-CRP (mg/L)	2.49 \pm 0.66	5.29 \pm 0.80*	0.002

There was a significant positive correlation with ferritin ($r = 0.306$) and TIBC ($r = 0.302$) in DM2. In group 2, a negative but significant correlation was found between IR and serum iron ($r = -0.28$) and serum transferrin saturation ($r = -0.316$) (Table-2).

Table-2: Correlation of insulin resistance with iron parameters, FBS and CRP (n= 111).

Correlations of insulin resistance with:	Spearman's Correlation Coefficient	P value
Serum transferrin saturation	-0.316	0.006*
Serum ferritin	0.306	0.008*
Serum iron	-0.28	0.016*
Serum total iron binding Capacity	0.302	0.009**
Fasting blood Glucose	0.596	0.000**
hs-CRP	0.089	0.45

DISCUSSION:

According to modern understanding, IR has traditionally been considered a key step in the pathogenesis of DM2. Glucose, insulin and C-peptide levels are well known IR markers. An important feature of this disease is also subclinical inflammation with active cytokines¹⁰⁻¹¹. Along with the production of cytokines, inflammation is accompanied by the production of acute phase proteins, mainly PCR. PCR impairs the ability of the insulin receptor to activate phosphatidylinositol 3-kinase and leads to IR development to induce serine phosphorylation at the insulin receptor. However, despite the high level of DM2 in our study, we could not find a significant relationship between hs-CRP and IR¹². Our results showed a significant correlation between high serum ferritin and IR. This discovery is in line with earlier research on the peoples of China and Korea. High levels of ferritin have been recognized as a feature of DM2. The relationship between iron and DM2 levels is complex. Insulin stimulates ferritin synthesis and activates iron overload, and vice versa, iron interferes with insulin inhibiting hepatic glucose production. On the other hand, ferritin acts as an indicator of pancreatitis and is therefore known as an IR marker¹³⁻¹⁴.

One study found 2.5-fold higher DM2 ferritin levels compared to healthy humans, but the percentage of transferrin receptors did not differ significantly, suggesting a link to elevated serum ferritin and negative iron levels. They can be caused by an inflammatory problem rather than an iron overload. Our results confirm the same hypothesis. Another study found that serum ferritin can be an indicator of systemic oil content and IR. Perhaps due to the selection bias, the possible relationship in our study group was not only related to diabetes¹⁵.

The results are consolidated with an IR correlation with low iron, low transferrin saturation, high TIBC and high ferritin, resulting in high ferritin levels not induced by iron overload, which then leads to T2DM irrespective of sex. inflammatory changes. The

effect of iron deficiency does not change the observation because ferritin levels are not clearly parallel to iron levels. Our study results did not show that sex is a discriminatory factor because inflammation in patients of any sex would be the same, but we still think the study has limitations.

CONCLUSION:

High ferritin levels without iron overload can affect glucose homeostasis. This can lead to the development of IR with inflammatory changes observed at high levels of PCR.

REFERENCES:

1. Elimam, Hanan, Azza M. Abdulla, and Inas Mohamed Taha. "Inflammatory markers and control of type 2 diabetes mellitus." *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 13, no. 1 (2019): 800-804. Elimam, Hanan, Azza M. Abdulla, and Inas Mohamed Taha. "Inflammatory markers and control of type 2 diabetes mellitus." *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 13, no. 1 (2019): 800-804.
2. Gholami, Mahsa, Mohammad Reza Rezvanfar, Mostafa Delavar, Mahdi Abdollahi, and Ali Khosrowbeygi. "Effects of coenzyme Q10 supplementation on serum values of gamma-glutamyl transferase, pseudocholinesterase, bilirubin, ferritin, and high-sensitivity C-reactive protein in women with type 2 diabetes." *Experimental and Clinical Endocrinology & Diabetes* 127, no. 05 (2019): 311-319.
3. Sanjeevi, Namrata, Jeanne Freeland-Graves, S. Natasha Beretvas, and Prageet K. Sachdev. "Trace element status in type 2 diabetes: A meta-analysis." *Journal of clinical and diagnostic research: JCDR* 12, no. 5 (2018): OE01.
4. Wang, Yeli, Woon-Puay Koh, Xueling Sim, Jian-Min Yuan, and An Pan. "Multiple biomarkers improved prediction for the risk of type 2 diabetes mellitus in Singapore Chinese

- men and women." *Diabetes & Metabolism Journal* 44, no. 2 (2020): 295-306.
5. Sun, Ping, Lei Lu, Jun Chen, Xiao Dan Liu, Qing Zhang, and Xu Wang. "AMPK α , hs-CRP and Fc γ R in diabetic nephropathy and drug intervention." *Experimental and therapeutic medicine* 15, no. 6 (2018): 4659-4664.
 6. Sciacqua, A., E. Ventura, G. Tripepi, V. Cassano, G. D'Arrigo, S. Roumeliotis, R. Maio et al. "Effect modification by ferritin on the relationship between inflammation and arterial stiffness in hypertensive patients with different glucose tolerance." (2020).
 7. Yan, Pijun, Yong Xu, Qin Wan, Jian Feng, Hua Li, Jun Yang, Haihua Zhong, and Zhihong Zhang. "Plasma neuregulin 4 levels are associated with metabolic syndrome in patients newly diagnosed with type 2 diabetes mellitus." *Disease markers* 2018 (2018).
 8. Wang, Yeli, Liang Sun, Xu Lin, Jian-Min Yuan, Woon-Puay Koh, and An Pan. "Retinol binding protein 4 and risk of type 2 diabetes in Singapore Chinese men and women: a nested case-control study." *Nutrition & metabolism* 16, no. 1 (2019): 3.
 9. Singh, Nikita, Harsh Vardhan Chawla, Sageeta Bhattacharya, Vivek Sharma, Arun Kumar, Asha Kumari, Anurag Amroz Singh, and Gini Garima. "A cross-sectional study on association of high-sensitivity C-reactive proteins (HS-CRP) with dyslipidemia in type 2 diabetic patients of Haryana region." *International J. of Healthcare and Biomedical Research* 7, no. 02 (2019): 30-39.
 10. Guo, Wen, Yingyun Gong, Jie Li, Pei Qin, Jing Lu, Xiaona Li, Wenfang Zhu, Nianzhen Xu, Hongwen Zhou, and Qun Zhang. "Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus." *Nutrition, Metabolism and Cardiovascular Diseases* 29, no. 8 (2019): 815-821.
 11. Algenstaedt, Petra, Alexandra Stumpenhagen, and Johannes Westendorf. "The effect of *Morinda citrifolia* L. fruit juice on the blood sugar level and other serum parameters in patients with diabetes type 2." *Evidence-Based Complementary and Alternative Medicine* 2018 (2018).
 12. Jafarnejad, Sadegh, Virginia Boccardi, Banafshe Hosseini, Mohsen Taghizadeh, and Zahra Hamedifard. "A meta-analysis of randomized control trials: the impact of vitamin C supplementation on serum CRP and serum hs-CRP concentrations." *Current pharmaceutical design* 24, no. 30 (2018): 3520-3528.
 13. Yang, Min, Changlin Ni, Baocheng Chang, Zhenhuan Jiang, Yanjuan Zhu, Yunzhao Tang, Zhu Li, Chenguang Li, and Bin Li. "Association between serum total bilirubin levels and the risk of type 2 diabetes mellitus." *Diabetes research and clinical practice* 152 (2019): 23-28.
 14. Cheng, Li-Shan, Wen-Jun Tu, Yuan Shen, Li-Jun Zhang, and Kangxiang Ji. "Combination of high-sensitivity C-reactive protein and homocysteine predicts the post-stroke depression in patients with ischemic stroke." *Molecular neurobiology* 55, no. 4 (2018): 2952-2958.
 15. Shankar, Prithvi, and K. Balaji. "Study of serum ferritin levels as an inflammatory marker and its relationship with HbA1c in type 2 diabetes mellitus."